FY2027 EPS Forecast for Bristol-Myers Squibb Cut by Analyst

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Research analysts at William Blair cut their FY2027 earnings per share estimates for Bristol-Myers Squibb in a research report issued to clients and investors on Tuesday, April 22nd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $6.44 for the year, down from their previous forecast of $6.54. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the previous year, the firm earned ($4.40) EPS. The firm's revenue was down 5.6% compared to the same quarter last year.

BMY has been the subject of a number of other reports. Citigroup raised their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Jefferies Financial Group lowered their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Truist Financial boosted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded up $0.55 during trading hours on Friday, hitting $48.45. The stock had a trading volume of 18,572,631 shares, compared to its average volume of 12,950,880. The stock has a market capitalization of $98.58 billion, a price-to-earnings ratio of -10.96, a PEG ratio of 2.07 and a beta of 0.41. The stock's 50-day moving average price is $56.37 and its two-hundred day moving average price is $56.53. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33.

Institutional Investors Weigh In On Bristol-Myers Squibb

Institutional investors have recently added to or reduced their stakes in the stock. Morse Asset Management Inc boosted its stake in Bristol-Myers Squibb by 25.0% in the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after acquiring an additional 2,000 shares in the last quarter. Tudor Financial Inc. acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth $250,000. Pine Valley Investments Ltd Liability Co grew its stake in Bristol-Myers Squibb by 1.3% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock worth $2,323,000 after buying an additional 575 shares during the last quarter. World Investment Advisors LLC increased its position in Bristol-Myers Squibb by 18.7% during the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after buying an additional 6,954 shares in the last quarter. Finally, Arvest Bank Trust Division purchased a new stake in Bristol-Myers Squibb in the third quarter valued at about $1,724,000. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 1,823 shares of the company's stock in a transaction on Friday, February 14th. The shares were acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.12%. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.